Is the price fair?
What XERS's price assumes
Xeris Biopharma Holdings, Inc. trades at 121× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
121
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · 4.99× the median: the market pays up for this one
- Price / sales
- 3.27
Price / sales · as of 2026-Q1
- Price / book
- 79.2
Price / book · as of 2026-Q1
- EV / sales
- 3.62
EV / sales
Details›
- Price / book2026-Q1
- 79.2
- EV / EBIT2026-Q1
- 31.8
- EV / sales2026-Q1
- 3.62
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Market capitalisation
- $1.28B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #14 of 29 by Smart Score